جميع الدراسات
التوظيفالمرحلة 1تدخلي

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

This is a new research study testing an investigational medicine called SRP-1005 for people living with Huntington's disease. It's an early-stage trial, meaning it's the very first time this specific medicine is being given to humans. Researchers want to understand if SRP-1005 is safe and how it works in the body of people with Huntington's. Some participants will receive SRP-1005, while others will receive a placebo (a dummy medicine with no active ingredients). This helps researchers compare the effects accurately. The study is being carried out in different medical centres.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 1
الراعي
Sarepta Therapeutics, Inc.
الهدف من التسجيل
32
ابدأ
12 مايو 2026
التاريخ المتوقع للانتهاء
30 نوفمبر 2027

ما هو موضوع هذه الدراسة؟

This research is an important first step in understanding a new medicine called SRP-1005 for Huntington's disease. Huntington's is a condition that affects the brain and can cause uncontrolled movements, problems with thinking, and changes in mood. Currently, there is no cure for Huntington's disease, so finding new ways to help manage or slow down the condition is crucial.

The main goal of this study is to find out if SRP-1005 is safe for people to take and to see how their bodies react to it. Because it's the 'first-in-human' study, it means no one has received this particular medicine before. This is a standard process for all new medicines before they can be further developed. Participants in the study will either receive SRP-1005 or a placebo, which looks exactly like the study medicine but doesn't contain any active ingredients. This allows researchers to compare the effects and determine if the medicine is making a difference.

This early stage of research, called Phase 1, focuses on safety. If the medicine is found to be safe and shows promising signs, it might then move on to larger studies to test how well it works. This kind of research is vital for developing future treatments for Huntington's disease.

النقاط الرئيسية

  • This is an early-stage study testing a new medicine for Huntington's disease.
  • The main goal is to check the medicine's safety in people for the first time.
  • Participants will receive either the new medicine or a placebo.
  • It requires specific genetic diagnosis and stage of Huntington's disease.
  • Regular clinic visits, blood tests, MRIs, and lumbar punctures are part of the study.
  • يمكنك التوقف عن المشاركة في أي وقت.

من قد يكون مؤهلاً؟

To take part in this study, you would need to be diagnosed with Huntington's disease, and your diagnosis must be confirmed by genetic testing. Your condition should be at a specific stage, either what doctors call 'Stage 2' or 'Mild Stage 3' according to a special assessment tool for Huntington's disease.

There are also some things that might mean you can't join. For example, if you have other serious brain or body illnesses, or if you have certain infections like HIV or hepatitis. You also can't have recently taken part in other studies testing new medicines or specific therapies for Huntington's disease.

Your age is also a factor; participants need to be between 21 and 70 years old. If you, or your partner, could have children, you would need to agree to use effective contraception during the study and for about three months afterwards. Pregnant or breastfeeding individuals cannot participate. The study team will discuss all these points with you in detail.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. I have a confirmed genetic diagnosis of Huntington's disease.
  2. My Huntington's disease is classified as Stage 2 or Mild Stage 3.
  3. I am between 21 and 70 years old.
  4. I don't have other serious medical conditions or infections like HIV.
  5. I haven't recently taken part in other drug trials for Huntington's disease.
  6. I am not pregnant or breastfeeding, and I understand contraception requirements.
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part, you'll have regular visits to a study clinic. These visits will involve various health checks, which might include blood tests, physical examinations, and possibly imaging scans like an MRI. You would also have a procedure called a lumbar puncture, which involves collecting a small sample of fluid from your spine, to understand how the medicine is affecting your body. This is a common procedure for studies looking at brain conditions.

During the study, you would receive either the investigational medicine, SRP-1005, or a placebo, which looks the same but contains no active medicine. Neither you nor your study doctor would know which one you are receiving. The study team will explain the schedule of visits, how often you'll take the medicine, and all the tests involved. The total duration of your participation, including follow-up, will be clearly explained by the research team.

المخاطر والفوائد المحتملة

Participating in any clinical trial involves both potential benefits and risks. For this early-stage study, the primary focus is on understanding the safety of SRP-1005. There is no guarantee that you will personally benefit from taking part, but your involvement could help researchers learn more about Huntington's disease and potentially contribute to developing future treatments for others. As with any medicine, there's a possibility of side effects from SRP-1005, and procedures like blood tests or lumbar punctures also carry minor risks, which the study team will explain fully. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

المواقع (5)

  • Westmead Hospital
    الرمز البريدي المؤكد
    ويستميد، أستراليا· التوظيف
  • مستشفى رويال ملبورن
    الرمز البريدي المؤكد
    باركفيل، أستراليا· التوظيف
  • New Zealand Brain Research Institute
    الرمز البريدي المؤكد
    Christchurch, New Zealand· التوظيف
  • Siloah AG
    الرمز البريدي المؤكد
    Gümligen, Switzerland· التوظيف
  • مستشفى جامعة ويلز
    الرمز البريدي المؤكد
    كارديف، المملكة المتحدة· التوظيف

أسئلة شائعة

ما هي دراسة "الأولى في البشر"؟

It means this is the very first time this particular medicine (SRP-1005) is being given to people. It's a key step to see if it's safe before more research can be done.

ما هو "العلاج الوهمي"؟

A placebo is a 'dummy' medicine that looks just like the real medicine but contains no active ingredients. It helps researchers fairly compare the effects of the actual medicine.

هل سأعرف إذا كنت أحصل على الدواء الحقيقي أم الدواء الوهمي؟

No, during the study, neither you nor your study doctor will know whether you are receiving SRP-1005 or the placebo. This is done to ensure the study results are unbiased.

ما هو البزل القطني؟

A lumbar puncture is a procedure where a small needle is used to collect a sample of fluid from your lower back, usually to check for certain markers or how a medicine is affecting your brain and spinal cord.

هل يمكنني التوقف عن المشاركة في الدراسة إذا غيرت رأيي؟

Yes, you are completely free to withdraw from the study at any time, for any reason. Your decision will not affect your routine medical care.

كيفية معرفة المزيد

Sarepta Therapeutics Inc., For Clinical Trial Information, Select Option 4

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A First-in-human Study of the Effects of SRP-1005 in Partici… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.